Prostate Cancer Detection with IsoPSA

LCD Information Document Information Source LCD ID N/A LCD ID L39284 Original ICD-9 LCD ID Not Applicable LCD Title Prostate Cancer Detection with IsoPSA® Proposed LCD in Comment Period N/A Source Proposed LCD DL39284 Opens in a new window Original Effective Date For services performed on or after 11/20/2022 Revision Effective Date For services performed on or after 11/06/2025 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 10/06/2022 Notice Period End Date 11/19/2022 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations, and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.” 42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 3, Section 190.31 Prostate Specific Antigen Chapter 1, Part 4, Section 210.1 Prostate Cancer Screening Tests CMS IOM Publication 100-04, Medicare Claims Processing Manual, Chapter 16 Laboratory Services CMS IOM Publication 100-08, Medicare Program Integrity Manual, Chapter 13, Section 13.5.4 Reasonable and necessary Provision in an LCD Coverage Indications, Limitations, and/or Medical Necessity The IsoPSA® test will be considered medically reasonable and necessary when all the following are met: Testing of men 50 years of age and older who have a confirmed* moderately elevated PSA (greater than 4 and ≤ 25 ng/mL) AND No other relative contraindication for prostate biopsy including: Less than a 10-year life expectancy *PSA elevation should be verified after a few weeks under standardized conditions (e.g., no ejaculation, manipulations, and urinary tract infections) in the same laboratory or other CLIA approved laboratory before considering a biopsy. Summary of Evidence Background Screening modalities for prostate cancer(PCA) include digital rectal exam (DRE) and prostate-specific antigen (PSA) test at a frequency of every twelve months for men ages fifty and over in effort to detect increased risk for adenocarcinoma of prostate.1 PSA is a reliable immunocytochemical marker for adenocarcinoma of the prostate. However, screening and early treatment of prostate cancer have come under scrutiny due to concerns for over diagnosis of low-risk cancers.2 Guidelines have been updated due to studies to refine the use of PSA, which remains the primary screening test.1-3 Investigations into adjunctive testing may provide opportunities to avoid biopsies and reduce overdiagnosis.2 IsoPSA® is a blood-based single parameter, structure-based assay for improved detection of high-grade prostate cancer. The test partitions isoforms of prostate-specific antigen with an aqueous two-phase reagent.4 The test aims to improve specificity by testing specific changes in PSA that arise specifically in cancer cells and would not be affected by conditions such as prostate hyperplasia, inflammation, or age that reduce the specificity of the standard PSA assays.4 Evidence Review Klein et al.4 2017 was an industry-sponsored multi-centered prospective study that included 261 men scheduled for prostate biopsy due to rising PSA level or suspicious digital rectal exam. The study was conducted at five different academic and community centers within the United States over 15 months. The primary study endpoint was the presence or absence of cancer and cancer grade as detected by ultrasound or MRI fusion biopsy. Exclusion criteria included serum PSA<2 ng/ml; recent (<72 hours) prostate manipulation, including DRE; recent (<2 weeks) urinary tract infection and/or prostatitis; recent (<30 days) prostate surgery, urinary catheterization, prostate infarction, or endoscopic evaluation; and other urinary tract malignancy. Out of 434 samples collected, 173 were excluded. Reasons for exclusion included prolonged storage greater than ninety days, canceled biopsies, the breach of sample collection protocol, shipping delays, or not meeting study protocol. The research aimed to assess two clinical performance objectives: the discriminatory power between malignant and non-malignant prostate conditions and between high-grade and low-grade cancers versus benign pathology. This population had an overall prevalence of 53% for prostate cancer, with 33.7% of cancers considered high-grade. They utilized receiver operating characteristic analysis to determine the discriminatory power measurement. In this preliminary analysis, they utilized decision curve analysis to access the clinical utility of the models by comparing the two extremes, no biopsy to biopsy for all (current patient cohort), and comparison against the modified prostate cancer prevention trial risk calculator 2.0. They reported results were: “for cancer versus no cancer endpoint, the area under the curve (AUC) was 0.79 (95% CI 0.73–0.84) for IsoPSA® versus 0.61 (95% CI 0.54–0.67) for total PSA (p < 0.001). For high-grade cancer versus low-grade cancer/benign histology, the AUC was 0.81 (95% CI 0.74–0.86) for IsoPSA® versus 0.69 (95% CI 0.61–0.75) for total PSA (p < 0.005)”. Using the pre-selected cutoff to recommend a biopsy, they reported a 48% reduction in false-positive biopsies with IsoPSA®. Utilizing a cutoff selected to identify men at low risk of high-risk disease, they reported a 45% reduction in the false-positive rate. They acknowledged that the test was not yet validated. The authors conclude that IsoPSA® outperformed PSA in predicting prostate cancer risk. The authors acknowledge that clinical and demographic parameters including age, race, and prostate volume could impact the clinical performance of the IsoPSA® test was not evaluated in this study which focused on the test’s clinical performance. They also acknowledge weaknesses in the study, including lack of central or standardized pathology review of the biopsies, a lack of distinction between primary and repeat biopsies, and variability in the use of MRI for decisions on the need for in the technique used in biopsies. Additional weakness includes the study design was a prospective trial without controls. This was not designed or powered for superiority, although the authors suggest the test outperformed standard PSA test. Age, race, prostate volume, presence of benign prostatic hypertrophy (BPH) was not evaluated but could impact results. Various pathological labs and methods for biopsy may have some variability that was not controlled, introducing a risk of bias. The primary endpoint was the clinical performance of the test in discriminating power of IsoPSA® for the presence of high-grade prostate cancer versus low-grade cancer or benign pathology. Using the data from Klein et al.4 a cutoff value of 17% was selected as the predicted probability of high-grade prostate cancer. The authors concluded using a cutoff of 17% yielded 93% negative predictive value. They calculate that this would reduce unnecessary prostate biopsies by 43%. Using modeling, they estimate that out of 1000 subjects; the test would miss twenty-two high-grade cancers, of which seven would have been Gleason sum 4 + 3 or higher. A sub-analysis of the African American participants showed similar results to the original combined cohort. Additional analysis on the biopsy technique segregated biopsies done by ultrasound compared to MRI guidance. They observed significant improvement in the IsoPSA® AUC when the biopsies were performed under MRI guidance. The number of biopsies done under MRI guidance increased from 4%4 to 41% in this study. Strengths of the study include using a new patient cohort, the addition of sub-analysis for African Americans and based on biopsy type, test run in the same lab, and pre-specified fixed outcome measurements defined by the previously published study. Weaknesses of this study include study design as a prospective trial without a control group. While the authors state the test had superior performance to PSA, the trial did not compare the performance of IsoPSA® to PSA directly, which would require an appropriately designed and powered superiority study or non-inferiority study to demonstrate at least equally accurate. While the study addressed the test's clinical performance (validity), it did not address the clinical utility. The lack of standardized biopsy technique and lack of central pathology review introduces a risk of bias. Age, prostate volume, presence of BPH were not evaluated but could impact results. The authors acknowledge a significant increase in MRI guidance for the biopsies, which is more accurate than the ultrasound guidance and cannot exclude selection bias. The primary outcome was to determine the clinical utility of IsoPSA® based on two things. One, provider willingness to use the test (test utilization) and two, the change in provider behavior as assessed by how IsoPSA® influenced recommendations for biopsy and MRI. Consistency between IsoPSA® results and recommendations for prostate biopsy was also considered. Changes in recommendations (either for or against) in 60.2% (442/734) for decisions on prostate biopsy and 6.0% (44/734) for decisions on MRI resulted based on the utilization of IsoPSA®. Results included a 55% (284 vs 638) net reduction in recommendations for prostate biopsy for men with total PSA >4 ng/ml who underwent IsoPSA® testing. A 9% reduction in recommendations for MRI was observed. A correlation was observed between IsoPSA® results and provider recommendations for prostate biopsy, with 87% of patients with an IsoPSA® index above the threshold recommended for biopsy and 92% of patients with an IsoPSA® index below the threshold not recommended for biopsy. Strengths of this study include a large number of providers representing real-world clinical practice including a broad range of practice styles, education and experience. Recruitment of patients ranged across varied practice settings, and participating providers served as intra-provider and intra-patient controls for both pre- and post-IsoPSA® clinical decision making. A standardized reporting module was utilized to record the influence of IsoPSA® on management decisions. Limitations of this study include patient compliance with provider recommendations for or against biopsy post-IsoPSA® were not assessed, a lack of long-term outcome data, and lack of a control group. Cost analysis studies were excluded from evidence review.7 Klein et al. 2022 (10) conducted a prospective, multicenter study at eight academic and community sites between August 2015 and August 2020. IsoPSA® was performed in 888 men > 50 years with total PSA > 4ng/ml scheduled for prostate biopsy. The primary outcome of this study was to estimate the performance, sensitivity, specificity, and predictive characteristics of IsoPSA®. Secondary outcomes were to identify the risk of High-Grade prostate cancer (Gleason Score ≥ 7) and any PCa (Gleason Score ≥ 6) in men ≥ 50 years of age with a pre-biopsy total PSA ≥4 ng/ml undergoing diagnostic biopsy and to determine cancer status when tested per protocol. The secondary outcome was to compare the diagnostic accuracy of IsoPSA® to total PSA and percent free PSA based on receiver operating characteristic (ROC) analysis. Exploratory outcomes were to assess the performance of IsoPSA® using ROC analysis in subgroups with total PSA 4 to 10 ng/ml, total PSA > 10 ng/ml, and in relation to prior biopsy status. Results included a disease prevalence of 35.6% (High-Grade PCA) and 58.9% (any PCA). The area under the ROC was 0.783 (High-Grade PCA) and 0.770 (any PCA). The High-Grade PCA endpoint, AUC was 0.783 (95% CI 0.752−0.814) for IsoPSA® vs. 0.672 (95% CI 0.639−0.706) for total PSA and 0.724 (95% CI 0.690 −0.758) for percent free PSA (p< 0.001). An estimated 46% (High-Grade PCA) and 42% (any PCA) of biopsies could be avoided in low-risk patients when utilizing IsoPSA® index cutoffs. Forty percent (354/888) subjects had a prior negative biopsy. In the group with at least one prior biopsy, IsoPSA® yielded a moderate AUC (0.82), a modest specificity (46%) and a good NPV (95%) for high-grade PCa on subsequent biopsy in 202 subjects with prior negative biopsies. These findings suggest IsoPSA® accuracy is not influenced by previous negative biopsy. The study suggests that IsoPSA® is unaffected by the use of alpha blockers or 5α-reductase inhibitors. The study data suggests that biopsy should be performed regardless of MRI findings for an IsoPSA® index >6 based on the information that MRI misses 20% of high-grade cancers. The authors report that IsoPSA® maintained statical accuracy across a broad range of elevated total PSA ranging from 4-100 ng/mL in 888 subjects. 24% (217/888) of study subjects had a PSA >10 ng/mL. 54 subjects (14.8%) of the sub-set with PSA >10-25 ng/mL had a negative biopsy while 44 (21.3%) has low grade PCA and 96 (30.4%) had high-grade PCA. However, only 23 subjects or 2.5% (23/888) had total PSA values >25 ng/mL with 20 of those predictably having high grade PCA (Gleason >7). Specificity (SP) and NPV (negative predictive value) decreased modestly in the group with total PSA >10 ng/mL and further breakdown of the small sub-set with PSA> 25 (n=23) was not reported in the study. Strengths of this study include the prospective, multicenter design, the large sample size, comparison of total and percent free PSA, and use of gold standard prostate biopsy pathology comparison in all study participates. Limitations include of this study include lack of standardized biopsy techniques, decentralized pathology review, failure to account for false positive IsoPSA® or false negative biopsy results, lack of a control group, lack of long-term follow-up and risk of bias due to funding by laboratory that produces the test. Benidir et al. is a single center retrospective review of prospectively collected data from 2019-2021 following a consecutive cohort of 83 subjects with elevated IsoPSA levels (>6) and concerning PSA and/or digital rectal examination who had a prostate biopsy followed by radical prostatectomy (RP) within the same period. 44 subjects without pre-operative IsoPSA served as controls. Pre-operative prostate Magnetic Resonance Imaging (MRI) and adverse histopathologic and MRI features when comparing biopsy to RP histopathology were included in the analysis. Of the 83 subjects with elevated IsoPSA 82 had PCa (99%) on final pathology. There were no differences in concordance, downstaging, and upstaging GG rates from biopsy to RP between the IsoPSA group and control, however the IsoPSA group had statistically significant elevation in pre-operative PSA levels compared to the control group (7.8 ng/mL vs 5.2 ng/mL, respectively, P<.001). IsoPSA was not influenced by prostate MRI or pathological features suggesting IsoPSA is non-selective marker. The authors conclude elevated IsoPSA (>6) is a diagnostic tool that can detect clinically significant prostate cancer at the time of biopsy. Limitations include study design of retrospective review at a single center, modest sample size for elevated IsoPSA outcomes, comparator group had significantly lower IsoPSA values and there was a lack of a comparator group of patients with low IsoPSA values who ended up undergoing biopsy and/or eventual RP.9 National Comprehensive Cancer Network (NCCN) guidelines recommendations include consideration for the use of biomarker tests for men with persistent elevation in PSA between 3 to 10 ng/ml using a validated test (determined in peer-reviewed, multi-site studies using an independent cohort of patients) within the prostate cancer early detection algorithms.2,7 The algorithms breakdown the role of these test by age, risk factors for prostate cancer, and if the test is used to evaluate for possible initial biopsy versus management of biopsy results. As of 02/16/2022, they included percent-free PSA, 4Kscore, PHI, PCA3, ConfirmMDx, MPS, and IsoPSA® in the guidelines.9 U.S. Preventive Service Task Force Guidelines updated in 2018 recommend PSA screening with a “C” recommendation and did not mention adjunctive screening test.3 The American Urological Association (AUA) states that PSA derivatives and isoforms and novel urinary markers and biomarkers for screening with the goal of reducing prostate cancer mortality provide limited evidence to draw conclusions and should not be used for primary screening. Additionally, the use of these markers after PSA screening may be considered a secondary test for informed decisions making regarding the need for prostate biopsy or repeat biopsies, but “emphasized the lack of evidence that these tests will increase the ratio of benefit to harm”.10 Analysis of Evidence (Rationale for Determination) IsoPSA® aims to improve the existing standard of care PSA testing for the detection of high-grade prostate cancer. CGS released a non-coverage LCD draft in October 2021. Since that time, clinical utility data has been published and NCCN guidelines have been updated to include IsoPSA®. One of the initial concerns addressed in the draft LCD was while the test offered a 93% sensitivity, resulting in approximately twenty-two missed cancers in 1000 patients based on the mathematical models, there was uncertainty if this would provide confidence to providers to be comfortable not performing a biopsy.4,5. In Scovell et al.6 changes in recommendations were reported in 60.2% for decisions on prostate biopsy resulting in a 55% net reduction in recommendations for prostate biopsy demonstrating confidence in this real-world population to utilize the test in decision making. In addition, this study provides the clinical utility data that was previously lacking. At the time of the open meeting in June 2022 the impact of age, prostate volume, and comorbid conditions as well as use outside of the initial biopsy had not been investigated. Since the June 2022 meeting additional literature has been published that addresses the accuracy of IsoPSA® in men with BPH and on 5-APIs, prior initial biopsies, and a broader range of PSA levels (10). Based on this latest information, the restriction for benign disease and prior negative biopsies was removed. The range of PSA was expanded to allow baseline PSA levels from 4-25 ng/mL. However, we did not agree with expansion in the baseline PSA range of 26-100 ng/mL due to poor strength of data to support this range and concern for lack of long-term data on outcomes for missed cancers. The NCCN algorithm includes IsoPSA® test for use outside the areas investigated in the IsoPSA®studies, and CGS does not consider the use outside the population studied applicable. The limited coverage criteria align with the population studied in the IsoPSA® literature.

The IsoPSA® test will be considered medically reasonable and necessary when all the following are met: Testing of men 50 years of age and older who have a confirmed* moderately elevated PSA (greater than 4 and ≤ 25 ng/mL) AND No other relative contraindication for prostate biopsy including: Less than a 10-year life expectancy *PSA elevation should be verified after a few weeks under standardized conditions (e.g., no ejaculation, manipulations, and urinary tract infections) in the same laboratory or other CLIA approved laboratory before considering a biopsy.